Skip to main content

Table 1 Clinical and demographic characteristics of groups

From: Comprehensive left ventricular mechanics analysis by speckle tracking echocardiography in Chagas disease

Variables

Chagas

Controls

Ch1A (n = 8)

Ch1B (n = 13)

Ch2 (n = 17)

Ch3 (n = 9)

C1 (n = 58)

C2 (n = 7)

C3 (n = 19)

Age (y)a

56 ± 7c

54 ± 12c

56 ± 12

56 ± 9

37 ± 12

47 ± 9

50 ± 11

Gender Mb

1 (12 %)

4 (31 %)

8 (47 %)

3 (67 %)

25 (43 %)

3 (43 %)

10 (53 %)

Weight (Kg)a

66.3 ± 10.6

67.5 ± 12.5

68.3 ± 12.3

65.2 ± 8.6

73.1 ± 15.9

69.5 ± 14.6

69.8 ± 16.2

Height (cm)a

157 ± 12d

160 ± 10d

165 ± 8

162 ± 6

169 ± 9

162 ± 10

164 ± 12

BS (m2)a

1.66 ± 0.19

1.70 ± 0.18

1.64 ± 0.18

1.70 ± 0.12

1.83 ± 0.21

1.74 ± 0.21

1.75 ± 0.25

BMI (kg/m2)a

26.9 ± 3.5

26.6 ± 4.8

25.0 ± 3.0

24.8 ± 3.0

25.4 ± 4.1

26.2 ± 4.4

25.6 ± 3.9

SAHb

4 (50.0 %)e

5 (38.5 %)e

5 (29.4 %)

4 (44.4 %)

0 (0 %)

1 (14.3 %)

8 (42.1 %)

DMb

1 (12.5 %)

1 (7.7 %)

1 (5.9 %)

1 (11.1 %)

0 (0 %)

1 (14.3 %)

1 (5.3 %)

DLPb

2 (25.0 %)f

4 (30.8 %)f

4 (23.5 %)

4 (44.4 %)

1 (1.7 %)

1 (14.3 %)

4 (21.1 %)

Smokerb

0 (0 %)

0 (0 %)

0 (0 %)

1 (11.1 %)

0 (0 %)

0 (0 %)

0 (0 %)

FC CHF (NYHA)b

 I

1 (12.5 %)g

7 (53.8 %)g

11 (64.7 %)

5 (55.5 %)

0 (0 %)

3 (42.9 %)

11 (57.9 %)

 II

0 (0 %)

1 (7.7 %)

5 (29.4 %)

4 (44.4 %)

0 (0 %)

3 (42.9 %)

7 (36.8 %)

 III

0 (0 %)

0 (0 %)

1 (5.9 %)

0 (0 %)

0 (0 %)

1 (14.3 %)

1 (5.3 %)

 IV

0 (0 %)

0 (0 %)

0 (0 %)

0 (0 %)

0 (0 %)

0 (0 %)

0 (0 %)

Therapyb

 Digital

0 (0 %)

0 (0 %)

0 (0 %)

3 (3.3 %)

0 (0 %)

2 (28.6 %)

5 (26.3 %)

 ACEi

3 (37.5 %)h

4 (30.8 %)h

14 (82.4 %)

7 (77.8 %)

0 (0 %)

3 (42.9 %)

15 (78.9 %)

 Bblock

1 (12.5 %)

1 (7.7 %)

12 (70.6 %)

9 (100 %)

2 (3.4 %)

6 (85.7 %)

19 (100 %)

 ARB

0 (0 %)

3 (23.1 %)i

2 (11.8 %)

2 (22.2 %)

0 (0 %)

3 (42.9 %)

4 (21.1 %)

 Ca++block

0 (0 %)

1 (7.7 %)

1 (5.9 %)

1 (11.1 %)

0 (0 %)

0 (0 %)

1 (5.3 %)

 Diuretics

3 (37.5 %)j

2 (18.2 %)j

7 (46.7 %)

5 (100 %)

0 (0 %)

2 (40 %)

12 (85.7 %)

 Aldost. Ant.

0 (0 %)

0 (0 %)

8 (47.1 %)

6 (66.7 %)

0 (0 %)

5 (71.4 %)

12(63.2 %)

Hemodynamics

 HR (bpm)

63.3 ± 4.1

61.9 ± 11.7k

63.7 ± 10.9

69.4 ± 9.7

71.1 ± 11.0

64.6 ± 12.4

78.6 ± 15.4

 SAP (mmHg)

132.0 ± 12.1

122.5 ± 12.3

122.4 ± 15.5

111.4 ± 18.0

122.4 ± 11.7

118.0 ± 28.5

121.7 ± 15.6

 DAP (mmHg)

79.1 ± 2.7

73.9 ± 12.7

74.0 ± 11.5

70.1 ± 12.6

74.6 ± 12.8

70.6 ± 12.8

79.5 ± 15.0

  1. BS body surface, BMI body mass index, SAH systemic arterial hypertension, DM diabetes mellitus, DLP dyslipidemia, FC CHF NYHA functional class of congestive heart failure, NYHA New York Heart Association, ACEi inhibitor of angiotensin converting enzyme, β block beta blocker; ARB angiotensin II receptor blocker, Ca ++ block calcium channel blocker; Aldost Ant aldosterone antagonist, HR heart rate, SAP systolic arterial pressure, DAP diastolic arterial pressure
  2. aContinuous variables expressed as mean ± SD. bCategorical variables expressed as frequency (proportion)
  3. cTukey test, p < 0.001, vs. C1
  4. dTukey; Ch1A, Ch1B p = 0.03 and p = 0.04, vs. C1
  5. eFisher’s exact test; Ch1A and Ch1B, p < 0.001, vs. C1
  6. fFisher’s exact test; Ch1A and Ch1B, p = 0.03; vs. C1
  7. gFisher’s exact test; Ch1A and Ch1B, p < 0.001, vs. C1
  8. hFisher’s exact test; Ch1A and Ch1B, p < 0.001, vs. C1
  9. iFisher’s exact test, p = 0.04, vs. C1
  10. jFisher’s exact test; Ch1A and Ch1B, p = 0.01, vs. C1
  11. kTukey test, p < 0.02, vs. C1
Back to article page

Cardiovascular Ultrasound

ISSN: 1476-7120

Contact us